- Home
- SISI vs VIRX Comparison
SISI vs VIRX Comparison
Compare SISI & VIRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SISI
- VIRX
- Stock Information
- Founded
- SISI 1997
- VIRX 2007
- Country
- SISI China
- VIRX United States
- Employees
- SISI N/A
- VIRX N/A
- Industry
- SISI Medicinal Chemicals and Botanical Products
- VIRX Biotechnology: Pharmaceutical Preparations
- Sector
- SISI Health Care
- VIRX Health Care
- Exchange
- SISI Nasdaq
- VIRX Nasdaq
- Market Cap
- SISI 5.9M
- VIRX 7.0M
- IPO Year
- SISI 2016
- VIRX N/A
- Fundamental
- Price
- SISI $1.65
- VIRX $0.15
- Analyst Decision
- SISI
- VIRX Buy
- Analyst Count
- SISI 0
- VIRX 4
- Target Price
- SISI N/A
- VIRX $5.00
- AVG Volume (30 Days)
- SISI 613.8K
- VIRX 2.3M
- Earning Date
- SISI 02-06-2025
- VIRX 03-06-2025
- Dividend Yield
- SISI N/A
- VIRX N/A
- EPS Growth
- SISI N/A
- VIRX N/A
- EPS
- SISI N/A
- VIRX N/A
- Revenue
- SISI $10,330,284.00
- VIRX N/A
- Revenue This Year
- SISI N/A
- VIRX N/A
- Revenue Next Year
- SISI N/A
- VIRX N/A
- P/E Ratio
- SISI N/A
- VIRX N/A
- Revenue Growth
- SISI 370.34
- VIRX N/A
- 52 Week Low
- SISI $1.63
- VIRX $0.13
- 52 Week High
- SISI $117.65
- VIRX $1.31
- Technical
- Relative Strength Index (RSI)
- SISI 40.35
- VIRX 42.57
- Support Level
- SISI $1.66
- VIRX $0.15
- Resistance Level
- SISI $1.89
- VIRX $0.19
- Average True Range (ATR)
- SISI 0.34
- VIRX 0.03
- MACD
- SISI -0.03
- VIRX -0.00
- Stochastic Oscillator
- SISI 1.18
- VIRX 12.00
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.
About VIRX Viracta Therapeutics Inc.
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.